Reviewing ALSFRS-R as the Established Endpoint for ALS Clinical Trials

Time: 2:30 pm
day: Day Two AM


• Demonstrating and quantifying challenges with the ALSFRS-R endpoint in its current state

• Showcasing evidence from alternative measurements to demonstrate impact on disease progression

• Outlining ongoing strategy to approach regulatory review through leveraging regulatory flexibility